和铂医药-B(02142)：抗TSLP全人源单克隆抗体(HBM9378/SKB378)慢性阻塞性肺疾病新药临床申请提交国家药品监督管理局

智通财经网11-08

智通财经APP讯，和铂医药-B(02142)发布公告，集团已向国家药品监督管理局提交了一项 HBM9378(或SKB378，由四川科伦博泰生物医药股份有限公司(06990)及公司开发HBM9378的合作伙伴所述)的新药临床试验申请(IND)，该药物是一款针对胸腺基质淋巴细胞生成素(TSLP)的全人源抗体，用于治疗慢性阻塞性肺疾病(COPD)。公司将与监管机构密切合作，完成申请流程。公司致力于为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481402231?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2024-11-08 17:10","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2481402231","market":"hk","top_or_hot":-1,"title":"和铂医药-B(02142)：抗TSLP全人源单克隆抗体(HBM9378/SKB378)慢性阻塞性肺疾病新药临床申请提交国家药品监督管理局","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，和铂医药-B(02142)发布公告，集团已向国家药品监督管理局提交了一项  HBM9378(或SKB378，由四川科伦博泰生物医药股份有限公司(06990)及公司开发HBM9378的合作伙伴所述)的新药临床试验申请(IND)，该药物是一款针对胸腺基质淋巴细胞生成素(TSLP)的全人源抗体，用于治疗慢性阻塞性肺疾病(COPD)。公司将与监管机构密切合作，完成申请流程。公司致力于为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1208555.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和铂医药-B(02142)：抗TSLP全人源单克隆抗体(HBM9378/SKB378)慢性阻塞性肺疾病新药临床申请提交国家药品监督管理局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和铂医药-B(02142)：抗TSLP全人源单克隆抗体(HBM9378/SKB378)慢性阻塞性肺疾病新药临床申请提交国家药品监督管理局\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 17:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1208555.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，和铂医药-B(02142)发布公告，集团已向国家药品监督管理局提交了一项  HBM9378(或SKB378，由四川科伦博泰生物医药股份有限公司(06990)及公司开发HBM9378的合作伙伴所述)的新药临床试验申请(IND)，该药物是一款针对胸腺基质淋巴细胞生成素(TSLP)的全人源抗体，用于治疗慢性阻塞性肺疾病(COPD)。公司将与监管机构密切合作，完成申请流程。公司致力于为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1208555.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1208555.html","article_id":"2481402231","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481402231","pubTimestamp":1731057030,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"和铂医药-B(02142)发布公告，集团已向国家药品监督管理局提交了一项 \nHBM...","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02142":"和铂医药-B","TSLP":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","BK1161":"生物科技","BK1574":"生物医药B类股","BK1583":"高瓴概念"},"translate_title":"Hebo Pharmaceutical-B (02142): Anti-TSLP fully human monoclonal antibody (HBM9378/SKB378) new drug clinical application for chronic obstructive pulmonary disease submitted to the National Medical Products Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1,"TSLP":1},"content_text":"智通财经APP讯，和铂医药-B(02142)发布公告，集团已向国家药品监督管理局提交了一项  HBM9378(或SKB378，由四川科伦博泰生物医药股份有限公司(06990)及公司开发HBM9378的合作伙伴所述)的新药临床试验申请(IND)，该药物是一款针对胸腺基质淋巴细胞生成素(TSLP)的全人源抗体，用于治疗慢性阻塞性肺疾病(COPD)。公司将与监管机构密切合作，完成申请流程。公司致力于为需要新型治疗选择的慢性阻塞性肺疾病患者提供精准治疗。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481402231"}